Is Bupropion a Mood Stabilizer?

Bupropion is not a mood stabilizer. It is classified as an antidepressant, approved by the FDA for major depressive disorder, seasonal affective disorder, and smoking cessation. The confusion is understandable, though, because bupropion behaves differently from most other antidepressants in ways that make it look, at first glance, like it might steady mood swings rather than just lift depression. Its unusual pharmacology and relatively lower risk of triggering mania in people with bipolar disorder have earned it a reputation that stretches beyond what the evidence supports.

What “Mood Stabilizer” Actually Means

The term “mood stabilizer” gets thrown around in psychiatry without a universally agreed-upon definition, which is part of why the question comes up in the first place. Researchers have pointed out that the label lacks clinical precision and have proposed frameworks to evaluate whether a drug genuinely stabilizes mood across multiple dimensions: treating acute mania, treating acute depression, preventing future manic episodes, and preventing future depressive episodes.¹ A true mood stabilizer, by that standard, works on both poles of bipolar disorder and keeps them from returning.

Lithium is the classic example. It treats mania, helps with bipolar depression, and reduces the risk of relapse on both sides. Valproate and certain atypical antipsychotics also fit the bill to varying degrees. Bupropion, by contrast, acts only on the depressive pole. It has no demonstrated anti-manic properties and is not used to prevent manic episodes. That alone disqualifies it from the mood-stabilizer category under any rigorous definition.

How Bupropion Works and Why It Seems Different

Most antidepressants prescribed today are SSRIs or SNRIs, which work primarily on serotonin or a combination of serotonin and norepinephrine. Bupropion takes a completely different route. It inhibits the reuptake of norepinephrine and dopamine without any meaningful effect on serotonin.² This distinct mechanism is why bupropion tends to be more activating than sedating, less likely to cause weight gain, and less likely to dampen sexual function.

The dopamine piece is especially relevant to the mood-stabilizer question. Research into bipolar disorder has long implicated dopamine: reduced dopamine activity appears to contribute to depression, while excessive dopamine activity is associated with mania.³ More detailed models suggest that changes in dopamine receptor availability and transporter levels in the brain’s reward circuits may drive the swings between depressive and manic states.⁴ Because bupropion boosts dopamine, you might expect it to push people toward mania. That it seems to do so less than other antidepressants is part of what gives it a stabilizing reputation, even though increasing dopamine is not the same as regulating it in both directions.

The Lower Mania-Switching Risk

One of the strongest reasons people associate bupropion with mood stability is its comparatively lower rate of triggering manic or hypomanic episodes in people with bipolar disorder. This is a real and well-documented finding, not just folklore. A systematic review of naturalistic studies found that older tricyclic antidepressants carry a higher likelihood of causing a mood switch into mania, while bupropion carries a lower rate.⁵

A head-to-head comparison among three antidepressants used alongside mood stabilizers found that venlafaxine was associated with the highest risk of switching into hypomania or mania, while bupropion carried the lowest risk, with sertraline falling somewhere in between.⁶ The ratio of full-blown switches to briefer hypomanic episodes was substantially lower with bupropion than with venlafaxine in both the acute and continuation phases of treatment.

But “lower risk” is not the same as “no risk.” Case reports have documented mania occurring with bupropion, and there is reason to think that exceeding the recommended daily dose increases that danger.⁷ The relative safety advantage seems to hold at standard doses but cannot be assumed to hold at higher ones.

Bupropion in Bipolar Depression

The depressive episodes of bipolar disorder tend to be more disabling and longer-lasting than the manic ones, and they are notoriously difficult to treat. Standard antidepressants carry the risk of destabilizing mood, so clinicians often look for options that can lift depression without tipping the scales toward mania. Bupropion has been used in this role, typically added on top of a mood stabilizer like lithium or valproate rather than prescribed alone.

A small open study of 13 patients with severe bipolar depression found that adding bupropion to existing mood-stabilizer regimens produced significant improvement: more than half of the patients saw their depression scores drop by at least 50 percent within four weeks.⁸ The combination was well tolerated in that small sample. However, these were open-label observations without a placebo comparison, so the results need to be read cautiously.

A much larger and more rigorous trial told a more sobering story. In a study of over 350 people with bipolar depression, adding an antidepressant (either bupropion or paroxetine) to a mood stabilizer did not improve recovery rates compared with adding a placebo. About 24 percent of those receiving the mood stabilizer plus antidepressant achieved durable recovery, compared with about 27 percent of those receiving the mood stabilizer plus placebo. Rates of mood switching were also similar between the two groups.⁹ That result was a splash of cold water: the antidepressant add-on didn’t help more than the mood stabilizer alone, and it didn’t cause more harm either. The implication is that for many people with bipolar depression, the mood stabilizer is doing the heavy lifting, and layering an antidepressant on top may not add much.

A meta-analysis looking specifically at bupropion in bipolar disorder found a significant treatment effect for depression but also found that bupropion’s rate of triggering a switch into mania was not significantly different from other antidepressants when the data were pooled together.¹⁰ That somewhat complicates the narrative that bupropion is uniquely safe in bipolar disorder, though individual comparative studies still tend to rank it favorably against specific alternatives like venlafaxine.

Rapid Cycling and a Niche Reputation

Rapid cycling, where a person with bipolar disorder experiences four or more mood episodes in a year, is one of the most treatment-resistant patterns in psychiatry. Antidepressants are generally viewed with suspicion in rapid cycling because they can accelerate the cycle. Bupropion has attracted attention here as a possible exception.

An early clinical series followed six rapid-cycling bipolar II patients who had not responded to conventional treatments. When bupropion was added to lithium (and in some cases thyroid hormone), all six improved significantly, and four showed dramatic and sustained responses over an average of two years. None developed hypomania or resumed rapid cycling during continued treatment, a sharp contrast to their prior experiences with other antidepressants.¹¹

This is the kind of finding that generates excitement but demands caution. Six patients, no control group, and open-label observation make it a clinical anecdote rather than a proof of concept. Still, it contributed to the clinical sense that bupropion occupies a special niche among antidepressants for people whose bipolar disorder is dominated by depressive episodes and who cycle rapidly through them. Larger controlled trials specifically in rapid-cycling populations would be needed to confirm this, and decades later, those trials remain thin on the ground.

Why Using It Alone in Bipolar Disorder Is Risky

Even if bupropion is gentler than many antidepressants in bipolar disorder, using any antidepressant as monotherapy in someone with bipolar disorder is broadly considered dangerous. The concern isn’t just an acute manic switch. Antidepressants without a mood stabilizer on board can destabilize the overall illness trajectory, potentially increasing cycling frequency or mixed features over time. Clinical guidelines consistently recommend that antidepressants in bipolar disorder be used only alongside a mood stabilizer, and bupropion is no exception to that rule.

The fact that bupropion is sometimes the antidepressant of choice in this setting doesn’t change its fundamental identity. It is being selected because it is the least disruptive antidepressant to pair with a mood stabilizer, not because it is doing the mood-stabilizing work itself. The mood stabilizer remains the backbone of treatment.

Beyond Bipolar Disorder and Emotional Regulation

The mood-stabilizer question sometimes comes from people who don’t have bipolar disorder but notice that bupropion seems to smooth out their emotional reactivity. This can happen in several contexts.

People with ADHD often experience emotional lability as part of the condition, and bupropion is sometimes prescribed off-label for ADHD. It has some effect on the core attentional symptoms, though the evidence for ADHD specifically is mixed, with small trials and limited long-term data.¹² When someone with ADHD and comorbid depression starts bupropion and feels their mood is more even, they may be experiencing improvement in the depressive symptoms that were amplifying the emotional dysregulation from ADHD. That is a real clinical benefit, but it is the antidepressant effect working on the depression, not a mood-stabilizing mechanism working on the ADHD.

There is also emerging interest in bupropion’s potential role in conditions marked by affective instability, such as borderline personality disorder. A case report on dextromethorphan-bupropion (a newer combination formulation) in a patient with borderline personality disorder and atypical depression documented subjective reports that emotions became “less intense and less permanent,” suggesting a possible shift in affect regulation. The authors noted this was especially interesting because affective instability in BPD often does not respond to standard antidepressants.¹³ This is a single case and involves a combination drug (dextromethorphan adds NMDA receptor antagonism), so drawing broad conclusions would be premature. But it illustrates why clinicians keep circling back to bupropion when looking for medications that might calm emotional volatility without the sedation and weight gain that come with many alternatives.

Preventing Relapse in Unipolar Depression

In straightforward major depression without bipolar features, bupropion has solid evidence for long-term relapse prevention. A continuation-phase trial showed that staying on bupropion after recovery significantly reduced the risk of relapsing into another depressive episode compared with switching to placebo, with the benefit becoming statistically clear around three months and lasting through nearly a year of follow-up.¹⁴

This kind of relapse prevention sometimes gets confused with mood stabilization. If you’ve been on bupropion for a year and your mood has been steady, it can feel like the drug is stabilizing your mood. In a sense, it is, but only the depressive pole. It is preventing depression from coming back. That is what antidepressants do when they work well. A mood stabilizer, by contrast, would also be expected to prevent mania or hypomania, and bupropion has no evidence for that.

How Your Genetics Affect Bupropion’s Behavior

Bupropion is metabolized primarily by a liver enzyme called CYP2B6, and genetic variation in the gene coding for that enzyme can meaningfully change how much active drug and how many metabolites circulate in your blood. People carrying certain gene variants (notably CYP2B6*6 and *18) had roughly a third lower concentrations of hydroxybupropion, the primary active metabolite, compared with people without those variants. A model including genotype and sex could account for about half the variability in hydroxybupropion levels between individuals.¹⁵

This matters for the mood-stabilizer question because a person with one genetic profile might experience bupropion as mildly activating and mood-neutral, while someone else might find it dramatically energizing or even destabilizing, all on the same dose. If you feel like bupropion either steadies you in an unusual way or makes your moods more unpredictable, your individual metabolism is probably part of the explanation. Pharmacogenomic testing is available and can identify these variants, though it is not yet standard of care before prescribing bupropion.

What Happens When You Stop

Stopping bupropion abruptly can produce withdrawal symptoms, which is another area where people sometimes conflate it with a mood stabilizer. A documented case of abrupt discontinuation led to irritable mood, anxiety, insomnia, headache, and generalized body aches.¹⁶ Gradual tapering is recommended to avoid these symptoms.

The rebound irritability and mood instability that can follow abrupt discontinuation sometimes reinforces the perception that the drug was “stabilizing” mood. But withdrawal-related mood changes happen with most antidepressants and many other psychiatric medications. They reflect the brain readjusting to the absence of a drug it had adapted to, not evidence that the drug was performing a mood-stabilizing function. SSRIs are well known for producing discontinuation syndromes, and nobody calls them mood stabilizers on that basis.

Bupropion’s Unique Position Among Antidepressants

Bupropion occupies a genuinely unusual place in the antidepressant landscape. Its dopamine and norepinephrine mechanism sets it apart from the serotonin-focused majority. Its lower rate of sexual side effects, weight gain, and emotional blunting makes it a popular choice for people who have struggled with those problems on other medications. Its relatively favorable profile in bipolar depression, while far from perfect, gives it a role that few other antidepressants can claim. And its availability in multiple formulations, from immediate-release to extended-release versions developed over more than 15 years of clinical use, means that dosing can be tailored to individual tolerability.

None of that makes it a mood stabilizer. It makes it a distinctive antidepressant with properties that happen to overlap with some of the goals of mood stabilization, specifically treating depression without making mania worse. The overlap is meaningful enough to explain why the question keeps coming up, but the distinction matters for treatment. If you need a mood stabilizer, bupropion cannot fill that role. If you need an antidepressant that plays well with mood stabilizers, bupropion is often the first name that comes up, and for good reason.